SG11201900975XA - Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same - Google Patents

Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same

Info

Publication number
SG11201900975XA
SG11201900975XA SG11201900975XA SG11201900975XA SG11201900975XA SG 11201900975X A SG11201900975X A SG 11201900975XA SG 11201900975X A SG11201900975X A SG 11201900975XA SG 11201900975X A SG11201900975X A SG 11201900975XA SG 11201900975X A SG11201900975X A SG 11201900975XA
Authority
SG
Singapore
Prior art keywords
international
drug
obs
fen
agonists
Prior art date
Application number
SG11201900975XA
Inventor
Stephen J Farr
Brooks Boyd
Original Assignee
Zogenix International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59955585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201900975X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zogenix International Ltd filed Critical Zogenix International Ltd
Publication of SG11201900975XA publication Critical patent/SG11201900975XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 March 2018 (01.03.2018) o I iolo 011111 00111100110111110 011 (10) International Publication Number WO 2018/037306 Al WIPO I PCT (51) International Patent Classification: A61K 45/06 (2006.01) A61K 31/551 (2006.01) A61K 31/05 (2006.01) A61P 3/04 (2006.01) A61K 31/137 (2006.01) A61P 25/08 (2006.01) A61K 31/36 (2006.01) (21) International Application Number: PCT/IB2017/054740 (22) International Filing Date: 02 August 2017 (02.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/379,183 24 August 2016 (24.08.2016) US 62/515,383 05 June 2017 (05.06.2017) US (71) Applicant: ZOGENIX INTERNATIONAL LIMITED [GB/GB]; Siena Court Broadway, Maidenhead, Berkshire SL6 1NJ (GB). (72) Inventors: FARR, Stephen J.; 12 Roberts Road, Orinda, California 94563 (US). BOYD, Brooks; 2313 Valley Street, Berkeley, California 94702 (US). (74) Agent: CLARK, Andrew Peter; J A Kemp, 14 South Square, Gray's Inn, London WC1R 5JJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: FORMULATION FOR INHIBITING FORMATION OF 5-HT AGONISTS AND METHODS OF USING SAME 2B Impact of STPNPAJCLB on Fen Exposure Impact of Fen on STPNPA/CLB Exposure Norfen_sim Norfen_obs Fen_sim Fen_obs STP_obs VPA_obs CLB_obs 04 06 08 10 1.2 1.4 16 18 2.0 04 06 0.8 10 12 1.4 1.6 18 20 Change Relative to Monotherapy AUC 0 _ 72 (%) Change Relative to STPNPA/CLB AUC 0 _ 72 (%) AUC 0 . 72.0bs for all analytes was calculated using R (Version 3.3.1) O N FIG. 2 O GC (57) : Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT agonists such as norfenfluramine with 2B O known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of C metabolite down thereby making the first drug safer. [Continued on next page] WO 2018/037306 Al MIDEDIMOMMIDIREIHNIMIIMEHINIMERVOIS EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201900975XA 2016-08-24 2017-08-02 Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same SG11201900975XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662379183P 2016-08-24 2016-08-24
US201762515383P 2017-06-05 2017-06-05
PCT/IB2017/054740 WO2018037306A1 (en) 2016-08-24 2017-08-02 Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same

Publications (1)

Publication Number Publication Date
SG11201900975XA true SG11201900975XA (en) 2019-03-28

Family

ID=59955585

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900975XA SG11201900975XA (en) 2016-08-24 2017-08-02 Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same

Country Status (14)

Country Link
US (6) US20180055789A1 (en)
EP (2) EP4201427A1 (en)
JP (2) JP2019526544A (en)
KR (2) KR20230021172A (en)
CN (1) CN109689103A (en)
AU (3) AU2017315273B2 (en)
CA (1) CA3032996A1 (en)
IL (2) IL290727B2 (en)
MX (2) MX2019001799A (en)
RU (2) RU2021106383A (en)
SG (1) SG11201900975XA (en)
TW (3) TWI722233B (en)
WO (1) WO2018037306A1 (en)
ZA (1) ZA201900766B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN108883399B (en) 2015-12-22 2021-06-22 周格尼克斯国际有限公司 Fenfluramine composition and preparation method thereof
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
WO2018037306A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
JP7424565B2 (en) 2018-06-15 2024-01-30 エルジー・ケム・リミテッド Decorative parts
EP3887481A4 (en) * 2018-11-30 2022-08-03 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
CA3153099A1 (en) 2019-09-17 2021-03-25 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
AU2020385385A1 (en) * 2019-11-21 2022-07-14 Shinkei Therapeutics, Inc. Cannabidiol and/or cobicistat combination drug therapy
TW202200152A (en) * 2020-04-30 2022-01-01 泰合生技藥品股份有限公司 Clobazam transdermal delivery system and uses thereof
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20230165810A1 (en) * 2021-12-01 2023-06-01 Zogenix International Limited Fenfluramine for treatment of conditions associated with spreading depolarization
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270984A (en) 1960-11-05
US3117160A (en) 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (en) 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-fluoroalkyl-phenylisopropylamine derivatives and their salts, processes for their preparation and pharmaceuticals based on them
DE2150399A1 (en) 1971-10-09 1973-04-12 Hoechst Ag Alpha-oximinobenzyl cyanides - useful as pesticide inters
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
DE3717434C1 (en) 1987-05-23 1988-09-15 Degussa Process for the preparation of m-trifluoromethylphenylacetonitrile
KR890003368A (en) 1987-08-06 1989-04-14 원본미기재 How to treat nausea and vomiting with certain substituted phenylalkylamino (and amino acid) derivatives and other serotonin-lowering agents
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (en) 1990-02-09 1993-09-01 Lab Mag Spa PROCEDURE FOR THE PREPARATION OF LEVO AND RIGHT FENFLURAMINA
FR2684552B1 (en) 1991-12-06 1995-04-28 Adir USE OF D-FENFLURAMINE AND FENFLURAMINE DERIVATIVES IN THE TREATMENT OF HYPERTENSION IN INSULIN RESISTANT SUBJECTS.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
JP3342491B2 (en) 1993-08-06 2002-11-11 ファルマシア・アンド・アップジョン・カンパニー 2-aminoindanes as selective dopamine D3 ligands
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
DK0762877T3 (en) 1994-06-03 2001-07-16 Thejmde Trust Meta-substituted arylalkylamines and their therapeutic and diagnostic uses
IT1298349B1 (en) 1996-05-29 2000-01-05 Alfa Chem Ital PROCESS FOR THE PRODUCTION OF 1 - (3-TRIFLUOROMETHYL) PHENYL-PROPAN- 2-ONE INTERMEDIATE IN THE SYNTHESIS OF PHENFLURAMINE
IT1292885B1 (en) 1997-04-28 1999-02-11 Alfa Chem Ital PROCESS FOR THE PRODUCTION OF (R) AND (S) - ALPHA-METHYL-3- (TRIFLUOROMETHYL) BENZENE-ETHANAMINE ISOMERS.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
DK1140061T3 (en) 1998-12-23 2003-08-25 Orphan Medical Inc Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
AU2001275095A1 (en) 2000-07-17 2002-01-30 Opt-E-Scrip, Inc. Single-patient drug trials used with accumulated database
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
EP1399015B1 (en) 2001-06-22 2010-01-27 Université Catholique de Louvain Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids
EP1411955A4 (en) 2001-07-31 2006-07-05 Wyeth Corp Sucralose formulations to mask unpleasant tastes
AUPR732601A0 (en) 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
EP2050460A1 (en) 2001-09-24 2009-04-22 Imperial Innovations Limited PYY and agonists thereof for modification of feeding behaviour
RU2317104C2 (en) 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Method for modifying alimentary behavior and application of pyy or its agonist as a preparation for modifying alimentary behavior
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
ATE486842T1 (en) 2002-03-12 2010-11-15 Merck Sharp & Dohme SUBSTITUTED AMIDES
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc Substituted 2,3-diphenyl pyridines
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
WO2006034465A1 (en) 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
CA2602899A1 (en) 2005-03-21 2006-09-28 Software Solutions Limited System for continuous blood pressure monitoring
EP1888030A1 (en) 2005-05-25 2008-02-20 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
JP2008546376A (en) 2005-06-16 2008-12-25 バイオノミックス リミテッド Methods for diagnosing and treating epilepsy by detecting mutations in the SCN1A gene
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
WO2007031846A2 (en) 2005-09-14 2007-03-22 University Of The Witwatersrand, Johannesburg Pharmaceutical composition
WO2007034476A2 (en) 2005-09-19 2007-03-29 Biolert Ltd A device and method for detecting an epileptic event
WO2007064675A2 (en) 2005-11-29 2007-06-07 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1971394A4 (en) 2005-12-28 2009-04-01 Neurovista Corp Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders
WO2007092469A2 (en) 2006-02-06 2007-08-16 Novartis Ag Combination of organic compounds
DE102006030113B4 (en) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphite-free high-temperature lubricant
WO2008025148A1 (en) 2006-08-31 2008-03-06 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators
KR20090053923A (en) * 2006-09-22 2009-05-28 노파르티스 아게 Heterocyclic organic compounds
US20080183498A1 (en) 2007-01-31 2008-07-31 Quintiles Transnational Corp., Inc. Methods and systems for site startup
PT2139467T (en) 2007-02-08 2016-12-16 Biogen Ma Inc Neuroprotection in demyelinating diseases
US20100120669A1 (en) 2007-02-28 2010-05-13 Anne Marie Jeanne Bouillot Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
US20100297181A1 (en) * 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
PE20110291A1 (en) 2008-09-05 2011-06-04 Gruenenthal Chemie PHARMACEUTICAL COMBINATION OF 3- (3-DIMETHYLAMINE-1-ETHYL-2-METHYL-PROPYL) -PHENOL AND AN ANTIEPYLEPTIC
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
KR20110067103A (en) 2008-10-09 2011-06-21 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 Liquid pharmaceutical formulation containing paracetamol
WO2010042780A2 (en) 2008-10-10 2010-04-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research Methods and compositions for treating status epilepticus and seizures causing status epilepticus
TWI424832B (en) 2008-12-15 2014-02-01 Proteus Digital Health Inc Body-associated receiver and method
JP2012520130A (en) 2009-03-09 2012-09-06 セルジーン コーポレーション Device for delivering a drug to a patient while restricting access to the drug by a patient who may be contraindicated in the drug, and method of use thereof
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
US20100324936A1 (en) 2009-04-22 2010-12-23 Suresh-Kumar Venkata Vishnubhatla Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
TW201127375A (en) 2010-01-08 2011-08-16 Eurand Inc Taste masked topiramate composition and an orally disintegrating tablet comprising the same
EP2545522B1 (en) 2010-03-09 2017-07-26 Perceptimed, Inc. Medication verification and dispensing
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (en) 2010-04-06 2011-11-04 Kakimori Suri Home medical care support system and method
EP2571858B1 (en) 2010-05-21 2018-06-20 Research Triangle Institute Phenylmorpholines and analogues thereof
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
CA2805760A1 (en) * 2010-07-30 2012-02-02 Merck Sharp & Dohme Corp. Inhibition of cyp3a drug metabolism
WO2012030927A2 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
WO2012056402A2 (en) 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
RU103209U1 (en) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" CLINICAL INFORMATION SYSTEM
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
JP5693325B2 (en) 2011-03-29 2015-04-01 小林クリエイト株式会社 Medical examination result output system and medical examination result output program
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US10092750B2 (en) 2011-11-11 2018-10-09 Neuroenabling Technologies, Inc. Transcutaneous neuromodulation system and methods of using same
US20140348966A1 (en) 2011-12-22 2014-11-27 Onesmo B. Balemba Garcinia buchananii baker compounds, compositions and related methods
WO2013112363A1 (en) 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (en) 2012-06-04 2017-02-08 富士通株式会社 HEALTH STATE JUDGING DEVICE AND ITS OPERATION METHOD
DE102012213040B4 (en) * 2012-07-25 2014-03-20 Infineon Technologies Ag Decoder for physically non-clonable functions by means of threshold decoding and corresponding method
WO2014078575A2 (en) 2012-11-15 2014-05-22 Galleon Pharmaceuticals, Inc. Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
PL3024463T3 (en) 2013-07-25 2020-10-05 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
EP3035926B1 (en) 2013-08-19 2020-07-29 The Regents of The University of California Compounds and methods for treating an epileptic disorder
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2015077057A1 (en) 2013-11-20 2015-05-28 Texas Southern University Methionine aminopeptidase inhibitors for treating infectious diseases
JP6147676B2 (en) * 2014-01-07 2017-06-14 東芝テック株式会社 Information processing apparatus, store system, and program
CN103886415A (en) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 Method and device for managing drugs
EP3136101B1 (en) 2014-04-22 2019-12-25 Tohoku University Method of testing for pulmonary hypertension
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
WO2016003966A1 (en) 2014-06-30 2016-01-07 University Of Cincinnati Non-invasive detection of spreading depolarization using scalp electroencephalography
RU2704749C2 (en) 2014-09-29 2019-10-30 Зодженикс Интернэшнл Лимитед Control system for managing distribution of medicinal products
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CN107427458A (en) 2015-02-06 2017-12-01 马瑞纳斯制药公司 Intravenous ganaxolone preparation and its purposes in treatment status epilepticus and other seizure disorders
DK3261640T3 (en) 2015-02-25 2022-07-11 Univ California 5HT AGONISTS FOR THE TREATMENT OF EPILEPSY DISORDERS
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
JP6668045B2 (en) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド Selective 5-HT receptor agonists and antagonists for treating Dravet syndrome
EP3505174B1 (en) 2015-06-17 2020-04-29 The Trustees of Columbia University in the City of New York Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
EP3316890B1 (en) 2015-06-30 2023-09-06 Neurad Ltd. Novel breathing control modulating compounds, and methods of making and using same
WO2017015309A1 (en) 2015-07-22 2017-01-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
KR20180054584A (en) 2015-08-24 2018-05-24 조게닉스 인터내셔널 리미티드 How to treat Lennox-Gastaut syndrome using fenfluramine
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
CN108883399B (en) 2015-12-22 2021-06-22 周格尼克斯国际有限公司 Fenfluramine composition and preparation method thereof
JP6753418B2 (en) 2016-01-14 2020-09-09 Ａｇｃ株式会社 Fluororesin-containing solution, method for producing fluororesin-containing solution, paint composition and painted article
ES2882175T3 (en) 2016-03-28 2021-12-01 Takeda Pharmaceuticals Co Compounds for use in the treatment of pulmonary hypertension
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
WO2018037306A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
CA3051699A1 (en) 2017-02-08 2018-08-16 Ovid Therapeutics Inc. Methods of treating seizure disorders and prader-willi syndrome
JP2020519594A (en) 2017-05-09 2020-07-02 ゾゲニクス インターナショナル リミテッド How to treat Douse syndrome with fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
US20190091173A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Method of increasing time between convulsive seizures
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US11352882B2 (en) 2018-03-12 2022-06-07 Cameron International Corporation Plug assembly for a mineral extraction system
EP3781671A4 (en) 2018-04-18 2022-01-26 The Trustees of Columbia University in the City of New York Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US20210113495A1 (en) 2018-07-10 2021-04-22 Zogenix International Limited Method of treating epilepsy or epileptic encephalopathy with fenfluramine in patients without pulmonary hypertension
CR20210095A (en) 2018-07-27 2021-06-01 Xenon Pharmaceuticals Inc Method for treating epilepsy
EA202191079A1 (en) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед METHODS FOR TREATMENT OF RETTA SYNDROME WITH FENFLURAMINE
EP3887481A4 (en) 2018-11-30 2022-08-03 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
US20220133652A1 (en) 2019-02-25 2022-05-05 Zogenix International Limited A formulation for improving seizure control
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
WO2023034115A1 (en) 2021-09-01 2023-03-09 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions

Also Published As

Publication number Publication date
ZA201900766B (en) 2020-10-28
US11406606B2 (en) 2022-08-09
US20220125743A1 (en) 2022-04-28
US20210393550A1 (en) 2021-12-23
CN109689103A (en) 2019-04-26
US11040018B2 (en) 2021-06-22
TWI722233B (en) 2021-03-21
MX2019001799A (en) 2019-06-13
RU2021106383A (en) 2021-04-05
US11786487B2 (en) 2023-10-17
US20190083424A1 (en) 2019-03-21
KR20190040237A (en) 2019-04-17
TW202308601A (en) 2023-03-01
CA3032996A1 (en) 2018-03-01
RU2019105059A (en) 2020-09-25
TW201821071A (en) 2018-06-16
JP2019526544A (en) 2019-09-19
KR20230021172A (en) 2023-02-13
US20210267916A1 (en) 2021-09-02
TW202131908A (en) 2021-09-01
AU2021204250B2 (en) 2022-09-01
IL290727A (en) 2022-04-01
MX2023005140A (en) 2023-05-26
AU2017315273A1 (en) 2019-03-07
IL264637B (en) 2022-04-01
US11759440B2 (en) 2023-09-19
US20180055789A1 (en) 2018-03-01
IL290727B1 (en) 2023-08-01
AU2021204250A1 (en) 2021-07-22
EP3518975A1 (en) 2019-08-07
RU2019105059A3 (en) 2020-11-25
WO2018037306A1 (en) 2018-03-01
RU2746000C2 (en) 2021-04-05
AU2022279469B2 (en) 2024-05-02
US20200246281A1 (en) 2020-08-06
US10603290B2 (en) 2020-03-31
AU2022279469A1 (en) 2023-02-02
AU2017315273B2 (en) 2021-04-29
TWI776407B (en) 2022-09-01
IL290727B2 (en) 2023-12-01
JP2022180461A (en) 2022-12-06
EP4201427A1 (en) 2023-06-28
NZ750691A (en) 2021-06-25

Similar Documents

Publication Publication Date Title
SG11201900975XA (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201803906PA (en) Control of cellular redox levels
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201808693WA (en) Anti-il-33 antibodies, compositions, methods and uses thereof
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201811237WA (en) Combination therapies
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900501RA (en) Cannabis composition
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201909837YA (en) Methods for treating lung disorders
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate